

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

MOC1

RRID:CVCL_ZD32

Type: Cell Line

Proper Citation

RRID:CVCL_ZD32

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_ZD32

Proper Citation: RRID:CVCL_ZD32

Description: Cell line MOC1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Squamous cell carcinoma of the mouse oral cavity

Defining Citation: [PMID:22086849](#), [PMID:22434099](#), [PMID:24668645](#), [PMID:25729643](#)

Comments: Characteristics: Indolent growth phenotype.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MOC1

Synonyms: Mouse Oral Cancer 1

Cross References: GEO:GSM1213076, GEO:GSM1213077, GEO:GSM1213078, GEO:GSM1213079, Kerafast:EWL001-FP, Millipore:SCC469, Wikidata:Q98127270

ID: CVCL_ZD32

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260905T181202+0000

Ratings and Alerts

No rating or validation information has been found for MOC1.

No alerts have been found for MOC1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

McIlvried LA, et al. (2026) CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma. *Cell reports*, 45(2), 116994.

Chen F, et al. (2026) CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2166.

Tsai TY, et al. (2026) The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. *Translational oncology*, 70, 102839.

Wang Q, et al. (2026) Androgen Receptor Signaling Induces CD8+ T-cell Dysfunction That Is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma. *Cancer research*, 86(9), 2286.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. *Molecular cell*.

Xu W, et al. (2026) PARD6G mediates resistance to PD-1 immune checkpoint blockade in head and neck squamous cell carcinoma. *International immunopharmacology*, 184, 116949.

Zhong W, et al. (2025) Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. *Nature cancer*, 6(7), 1157.

Zhang Y, et al. (2025) CDK4/6 Inhibitor Priming Enhances PD-1 Blockade via Sellhi Neutrophil-Induced Stat5a+ Progenitor Exhausted CD8+ T Cell. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e10501.

Grandis JR, et al. (2025) Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer. *Cancer cell*.

Li Y, et al. (2025) Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. *Journal of translational medicine*, 23(1), 403.

Tao ZY, et al. (2024) Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGF β Signaling. *Cancer research communications*, 4(2), 418.

Feng YY, et al. (2024) Synthetic lethal CRISPR screen identifies a cancer cell-intrinsic role of PD-L1 in regulation of vulnerability to ferroptosis. *Cell reports*, 43(7), 114477.

Tsai DE, et al. (2024) Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models. *iScience*, 27(9), 110854.

Gao J, et al. (2024) CCR7/DUSP1 signaling Axis mediates iCAF to regulates head and neck squamous cell carcinoma growth. *Cellular signalling*, 122, 111305.

Fay M, et al. (2024) TGF- β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. *iScience*, 27(8), 110520.

Saito S, et al. (2024) Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1934.

Li Y, et al. (2022) Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. *Molecular cell*, 82(20), 3901.